FDA Approves Enhertu for Unresectable or Pretreated HER2+ MBC
FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer
January 2, 2020
On Dec. 20, 2019, the U.S. Food and Drug Administration approved Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki) to treat people diagnosed with unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies. Read more...